Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
p27 siRNA
- Development stage
- Preclinical
- Lead developer
- Sound
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravitreal, Intraretinal, Subretinal, Subtenon, Peri-orbital, Retro-orbital, Trans-corneal, Trans-scleral, Ophthalmic, Intravenous, Subcutaneous, Oral, Rectal, Intranasal, Intraperitoneal
01
Overview
p27 siRNA is a proprietary small interfering RNA (siRNA) drug developed by Sound Pharmaceuticals in collaboration with the University of California, Los Angeles (UCLA). It is designed to inhibit the protein cyclin-dependent kinase inhibitor 1B, also known as p27Kip1. By inhibiting p27Kip1, the drug aims to stimulate the regeneration of auditory hair cells, offering a potential regenerative therapy for sensorineural hearing loss. The development of this drug has been supported by grant funding from the National Institute on Deafness and Other Communication Disorders (NIDCD) and the Office of Naval Research (ONR).
02
Targets
CDKN1B (Transmembrane emp24 domain-containing protein 7)
Beyond the preview
Go deeper on p27 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on p27 siRNA.